[go: up one dir, main page]

WO2008088524A3 - Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor - Google Patents

Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor Download PDF

Info

Publication number
WO2008088524A3
WO2008088524A3 PCT/US2007/025219 US2007025219W WO2008088524A3 WO 2008088524 A3 WO2008088524 A3 WO 2008088524A3 US 2007025219 W US2007025219 W US 2007025219W WO 2008088524 A3 WO2008088524 A3 WO 2008088524A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastrointestinal tract
epithelial proliferation
spondin
thrombospondin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/025219
Other languages
French (fr)
Other versions
WO2008088524A2 (en
Inventor
Kazuma Tomizuka
Makoto Kakitani
Takeshi Oshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Pharma KK
Nuvelo Inc
Original Assignee
Kirin Pharma KK
Nuvelo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Pharma KK, Nuvelo Inc filed Critical Kirin Pharma KK
Publication of WO2008088524A2 publication Critical patent/WO2008088524A2/en
Publication of WO2008088524A3 publication Critical patent/WO2008088524A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an agent for promoting epithelial proliferation and a method for promoting epithelial proliferation, particularly to an agent for promoting gastrointestinal tract-epithelial proliferation and a method for promoting gastrointestinal tract-epithelial proliferation. The present invention further relates to an agent for treatment or prevention of gastrointestinal tract-epithelium-associated diseases or disorders, and to a method for treating or preventing gastrointestinal tract-epithelium- associated diseases or disorders. The present invention further relates to the use of an R-spondin 1 variant protein, which lacks the thrombospondin type 1 repeat, or the nucleic acid encoding the same.
PCT/US2007/025219 2006-12-28 2007-12-10 Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor Ceased WO2008088524A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87745306P 2006-12-28 2006-12-28
US60/877,453 2006-12-28

Publications (2)

Publication Number Publication Date
WO2008088524A2 WO2008088524A2 (en) 2008-07-24
WO2008088524A3 true WO2008088524A3 (en) 2008-09-18

Family

ID=39529346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025219 Ceased WO2008088524A2 (en) 2006-12-28 2007-12-10 Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor

Country Status (1)

Country Link
WO (1) WO2008088524A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203352B2 (en) * 2007-07-02 2016-10-27 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
JP5931336B2 (en) 2007-07-02 2016-06-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for treating and diagnosing cancer
US9464275B2 (en) * 2008-08-21 2016-10-11 The Board Of Trustees Of The Leland Stanford Junior University Ex vivo culture, proliferation and expansion of intestinal epithelium
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
CN106167526A (en) 2011-07-15 2016-11-30 昂考梅德药品有限公司 RSPO bonding agent and its application
CA2878868A1 (en) 2012-07-13 2014-01-16 Austin L. Gurney Rspo3 binding agents and uses thereof
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
EP3193935A4 (en) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
US11180735B2 (en) 2016-10-28 2021-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods to preserve tumor-stromal interactions in culture and therapeutic predictive applications thereof
WO2021140209A1 (en) * 2020-01-10 2021-07-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Rspo1 proteins and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040418A2 (en) * 2003-10-10 2005-05-06 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt
WO2005072419A2 (en) * 2004-01-27 2005-08-11 Nuvelo, Inc. Gastrointestinal proliferative factor and uses thereof
WO2006104536A2 (en) * 2005-01-18 2006-10-05 Nuvelo, Inc. Polynucleotides encoding stem cell factor-like proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040418A2 (en) * 2003-10-10 2005-05-06 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt
WO2005072419A2 (en) * 2004-01-27 2005-08-11 Nuvelo, Inc. Gastrointestinal proliferative factor and uses thereof
WO2006104536A2 (en) * 2005-01-18 2006-10-05 Nuvelo, Inc. Polynucleotides encoding stem cell factor-like proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BINNERTS MINKE E ET AL: "R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 37, September 2007 (2007-09-01), pages 14700 - 14705, XP002486936, ISSN: 0027-8424 *
DATABASE UniProt [online] 3 October 2006 (2006-10-03), "R-spondin isoform 2 (R-spondin homolog) (Xenopus laevis).", XP002486937, retrieved from EBI accession no. UNIPROT:Q0H8S6 Database accession no. Q0H8S6 *
KIM K-A ET AL: "Mitogenic Influence of Human R-Spondin1 on the Intestinal Epithelium", SCIENCE, WASHINGTON, DC, vol. 309, 19 August 2005 (2005-08-19), pages 1256 - 1259, XP003014398, ISSN: 0036-8075 *
KIM KYUNG-AH ET AL: "R-Spondin proteins: a novel link to beta-catenin activation.", CELL CYCLE (GEORGETOWN, TEX.) JAN 2006, vol. 5, no. 1, January 2006 (2006-01-01), pages 23 - 26, XP002486935, ISSN: 1551-4005 *
PARMA P ET AL: "R-spondin1 is essential in sex determination, skin differentiation and malignancy", NATURE GENETICS 20061123 US, vol. 38, no. 11, 23 November 2006 (2006-11-23), pages 1304 - 1309, XP002486934, ISSN: 1061-4036 1546-1718 *

Also Published As

Publication number Publication date
WO2008088524A2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
WO2007090569A8 (en) Conditioned blood composition and method for its production
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
WO2007092622A3 (en) Compositions and methods for treating bone
WO2009027346A3 (en) 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2008080082A3 (en) Methods for modulating set and uses thereof
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2008127290A3 (en) Alginate and alginate lyase compositions and methods of use
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2008016643A3 (en) Certain chemical entities, compositions, and methods
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
EP2388317A4 (en) Gene coding for human glucocaine mutant, enzyme encoded therewith, recombinant vectors and hosts, pharmaceutical compositions and their use, methods for the treatment and prevention of diseases
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
WO2007134350A8 (en) Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867689

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867689

Country of ref document: EP

Kind code of ref document: A2